In this issue:
Tocilizumab in RA: 2-year follow-up
Long-term adalimumab for non-radiographic axial spondyloarthritis
Filgotinib with and without methotrexate for RA
Hip and knee replacement during the biological DMARD era
Guselkumab for palmoplantar pustulosis
Lebrikizumab for moderate-to-severe atopic dermatitis
Fezakinumab for moderate-to-severe atopic dermatitis
In utero anti-TNF-α exposure
Infliximab dose modification paradigms in CD
Please login below to download this issue (PDF)